https://scholars.lib.ntu.edu.tw/handle/123456789/563736
標題: | Current pharmacological approaches to prevent and treat post-menopausal osteoporosis | 作者: | RONG-SEN YANG Liu S.H. |
公開日期: | 2009 | 卷: | 3 | 期: | 1 | 起(迄)頁: | 42-53 | 來源出版物: | Recent Patents on Endocrine, Metabolic and Immune Drug Discovery | 摘要: | Osteoporosis characterized by low bone mass and structural deterioration of bone tissue; has a huge impact on public health through high morbidity, mortality and economic costs associated with resultant fractures. The prevention and treatment of fragility fractures in the osteoporosis patients worldwide becomes an important issue in the current clinical practice. Women often have an accelerated bone loss after menopause and result in a lower bone mass than men. Since the bone loss is irreversible, early prevention and treatment of osteoporosis is important in the early postmenopausal period. The goal of prevention needs to be not only effective, but also safe, to diminish the risk of vertebral, hip and other nonvertebral fractures. Non-pharmacological treatments, such as calcium, vitamin D, exercise and reduction of risk factors may diminish the impact of menopause and age-mediated bone loss. Current pharmacological options available include bisphosphonates, calcitonin, hormone replacement therapy, selective estrogen receptor modulators, teriparatide, and strontium ranelate, etc. Lots of natural products including dietary components and herbal products have also been demonstrated to be capable of modifying bone metabolism, particularly of inhibiting bone resorption. These natural products may provide as an alternative treatment for osteoporosis. More than 150 patents have recently been issued for the prevention and treatment of postmenopausal osteoporosis. The development of other new medications also sheds light on either prevention or treatment of osteoporosis, such as human monoclonal anti-RANKL antibody, cathepsin K inhibitors, and cannabinoid-based drugs. ? 2009 Bentham Science Publishers Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-70349219865&doi=10.2174%2f187221409787002958&partnerID=40&md5=9a4730ba3a304c5f4c93ce7f5cd332c2 https://scholars.lib.ntu.edu.tw/handle/123456789/563736 |
ISSN: | 1872-2148 | DOI: | 10.2174/187221409787002958 | SDG/關鍵字: | 25 acetylcimigenol xylopyranoside; adlay; alendronic acid; bisphosphonic acid derivative; calcitonin; calcium; calcium carbonate; Chinese drug; colecalciferol; conjugated estrogen; estradiol; estradiol plus norethisterone acetate; glycoside; herbaceous agent; ibandronic acid; isoflavone; parathyroid hormone[1-34]; piperazine estrone sulfate; raloxifene; risedronic acid; salcatonin; soybean protein; unclassified drug; vitamin D; zoledronic acid; article; bone mass; bone necrosis; bone pain; breast cancer; calcium blood level; cerebrovascular accident; continuous infusion; cost effectiveness analysis; deep vein thrombosis; dementia; dizziness; drug approval; drug bioavailability; drug contraindication; drug induced headache; drug safety; drug tolerability; dysphagia; environmental factor; epistaxis; esophagitis; esophagus ulcer; exercise; falling; flu like syndrome; gastrointestinal symptom; heart atrium fibrillation; hormonal therapy; hot flush; human; ischemic heart disease; leg cramp; limb pain; musculoskeletal pain; myalgia; nausea; nonhuman; orthostatic hypotension; phlebitis; postmenopause osteoporosis; priority journal; rhinitis; risk factor; side effect; stomach ulcer; vein thrombosis; venous thromboembolism; visual disorder; weight bearing |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。